scholarly journals Underserved Pacific Islanders With Locally Advanced Cervical Cancer Receive Higher Rates of Standard-of-Care Radiation Treatment Through the Pacific Island Health Care Project and Military Health System Compared to the Average U.S. Population

2021 ◽  
Author(s):  
Collin Sitler ◽  
Kristen P Bunch ◽  
David Padro ◽  
Caela R Miller

ABSTRACT Introduction Brachytherapy, with external beam radiation, increases survival in the treatment of locally advanced cervical cancer (LACC). In 2016, Robin et al. reported only 44% of patients received standard-of-care (SOC) brachytherapy in the USA. The Pacific Island Health Care Project has provided humanitarian medical care to women from the U.S. Associated Pacific Islands (USAPI) for three decades at Tripler Army Medical Center (TAMC), a military health care system (MHS) facility. We evaluated whether this underserved and understudied patient population received SOC treatment for LACC at TAMC. Materials and Methods The TAMC tumor registry was searched for all cervical cancer cases from 1997 to 2019. Subjects were excluded if they did not have stage IB2-IVA disease and were not from USAPI. The primary outcome was the overall utilization of brachytherapy, and statistical analysis was performed using the chi-square test. Results We identified 214 women with cervical cancer treated at TAMC, of which 67 met the study criteria. Ninety-two percent had squamous cell carcinoma on histology. Of the patients identified, 48 (71.6%, P < .001) were treated with brachytherapy. Fifteen (22.4%) patients received external radiation alone, and four (6.0%) received chemoradiation without brachytherapy. A post-hoc power analysis was conducted with a power of 91.3%. Conclusions Women with cervical cancer from USAPI in the PIHCP program treated at TAMC received significantly higher rates of SOC radiation treatment than the U.S. population on average. This highlights the ability of PIHCP, through the MHS, to deliver SOC treatment for cervical cancer to an otherwise underserved patient population.

2018 ◽  
Vol 23 (3-6) ◽  
pp. 158-163
Author(s):  
S. V Korepanov ◽  
A. F Lazarev ◽  
Valentina D. Petrova

Radiation therapy is the main method of treatment of locally advanced cervical cancer. However, this type of treatment, especially in combination with chemotherapy, often leads to complications from the indicators of homeostasis. The authors proposed to eliminate or mitigate hematological side effects to use as an accompanying therapy during chemo-radiation treatment of the original patented method of drugs from medicinal plants. There are Siberian ginseng (Eleutherococcus senticosus Maxim.), Badan (bergenia crassifolia), Birch buds (Gemmae Betulae), Pharmacy Chamomile (Matricaria Chamomilla), Plantago (Plantago major L.), St. John’s wort (Hypericum perforatum L. ), Licorice root (Glycirrhiza glabra uralensis L.), Bearberry (Arctostaphylos uva-ursi Spr.), Yarrow (Achillea millefolium L.), Dill (Anethum graveolens L.), Linseed (Linum usitatissimum L.) in the original method. In a randomized clinical trial in patients with locally advanced cervical cancer: primary group of 350 patients who received standard special chemo-radiation therapy on the background of the accompanying herbal medicine and a comparison group - 402 patients who received only standard, the special treatment have been examined a number of indicators of homeostasis. It was shown that in patients of the main group, the deviation from the normal level of blood parameters were less pronounced and returned to normal faster after treatment than in patients of the comparison group (p


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e18023-e18023
Author(s):  
Nidal Salim ◽  
Vladimir Nosov ◽  
Daria Zvereva ◽  
Olga Novikova ◽  
Anna Tedeeva ◽  
...  

e18023 Background: Concomitant chemoradiation therapy (CRT) that includes both external beam radiotherapy (EBRT) and brachytherapy (BT) is the current standard of care in treatment of locally advanced cervical cancer (LACC). Adaptive EBRT using volumetric modulated arc technology without BT allows dose escalation and decreases toxicities. Non-brachytherapy treatment is an evolving alternative approach provides geographical radiation accuracy but the oncological outcomes still to be evaluated. Methods: Patients with LACC (stages 1B3–IVA) who underwent non-brachytherapy CRT using adaptive EBRT with simultaneous integrated boost at our institution were evaluated prospectively from May 2015 to December 2019. All patients were initially assessed by a gynecologic oncologist, pelvic MRI and 18FDG-PET/CT scan were conducted. Follow-up pelvic examinations with cytology every 3 months and PET/CT at 3 and 12 months after completion of treatment were performed. Oncological outcomes and toxicities were assessed. Results: Twenty-one patients were analyzed: median age was 54 years (30–76 years); 19 patients had squamous cell histology and 2 had adenocarcinoma. Median follow-up was 32 months (8–56). The average dose administered to the gross tumor volume was 90.2 Gy (79.5–96.6), 79.8 Gy to all PET/MRI positive lymph nodes (63.0–89.7). No patents received BT; all but 3 received chemotherapy. Three-year local control was 100% (PFS = 90.4% and OS = 100%). There were 2 recurrences: a solitary skull lesion 18 months following CRT in a patient with mesonephric adenocarcinoma and a metastasis to a transposed ovary 15 months after CRT. No grade 3–4 toxicities were seen. Only 1 patient (4.7%) had late rectal grade II toxicity. Conclusions: Non-brachytherapy adaptive CRT for LACC is feasible. It allows for a significant dose escalation, thus providing better local control and likely increases PFS and OS at no cost of serious toxicity. Randomized studies comparing this approach to the current standard of care are needed.


2010 ◽  
Vol 20 (Suppl 2) ◽  
pp. S47-S48 ◽  
Author(s):  
Nicoletta Colombo ◽  
Michele Peiretti

Cervical cancer is the second most common cause of female cancer mortality worldwide. Concurrent chemoradiotherapy represents the standard of care for patients with stage IB2-IIIB cervical cancer. However, the lack of radiotherapy departments, especially in developing countries, the presumed high incidence of long-term complications, and the poor control of metastatic disease have brought about the development of different therapeutic approaches such as neoadjuvant chemotherapy followed by surgery. We reviewed the literature concerning the role of neoadjuvant chemotherapy for locally advanced cervical cancer.


Sign in / Sign up

Export Citation Format

Share Document